Advertisement

Advertisement

FBRX Stock Latest News

Forte Biosciences Shareholders Approve Directors and Governance Items

Company AnnouncementsForte Biosciences Shareholders Approve Directors and Governance Items

Forte Biosciences: Buy Rating Backed by FB102 Pipeline Momentum and Multiple Upcoming Clinical Catalysts

PremiumRatings

Forte Biosciences: Buy Rating Backed by FB102 Pipeline Momentum and Multiple Upcoming Clinical Catalysts

1M ago

Forte Biosciences reports Q1 EPS ($1.24), consensus ($1.16)

PremiumThe Fly

Forte Biosciences reports Q1 EPS ($1.24), consensus ($1.16)

1M ago

Forte Biosciences Prices $150 Million Public Offering

PremiumCompany Announcements

Forte Biosciences Prices $150 Million Public Offering

2M ago

Forte Biosciences 5.71M share Spot Secondary priced at $26.27

PremiumThe Fly

Forte Biosciences 5.71M share Spot Secondary priced at $26.27

2M ago

Forte Biosciences announces common stock offering, no amount given

PremiumThe FlyForte Biosciences announces common stock offering, no amount given

2M ago

Forte Biosciences reports FY25 EPS ($4.71) vs. ($12.17) last year

The Fly

Forte Biosciences reports FY25 EPS ($4.71) vs. ($12.17) last year

3M ago

Is FBRX a Buy, Before Earnings?

Pre-Earnings

Is FBRX a Buy, Before Earnings?

3M ago

Forte Biosciences initiated with an Outperform at Evercore ISI

PremiumThe Fly

Forte Biosciences initiated with an Outperform at Evercore ISI

7M ago

Forte Biosciences Reports Increased R&D Costs Amid Clinical Progress

PremiumCompany Announcements

Forte Biosciences Reports Increased R&D Costs Amid Clinical Progress

7M ago

Forte Biosciences reports Q3 EPS (99c), consensus ($1.07)

PremiumThe Fly

Forte Biosciences reports Q3 EPS (99c), consensus ($1.07)

7M ago

Forte Biosciences Inc. Launches Promising Study on Alopecia Areata Treatment

PremiumCompany Announcements

Forte Biosciences Inc. Launches Promising Study on Alopecia Areata Treatment

8M ago

Forte Biosciences Advances Celiac Disease Treatment with FB102 Study

PremiumCompany AnnouncementsForte Biosciences Advances Celiac Disease Treatment with FB102 Study

8M ago

Forte Biosciences’ FB102 Study: A Potential Breakthrough in Vitiligo Treatment

Company Announcements

Forte Biosciences’ FB102 Study: A Potential Breakthrough in Vitiligo Treatment

8M ago

Forte Biosciences Reports Q2 2025 Financial Results

Company Announcements

Forte Biosciences Reports Q2 2025 Financial Results

10M ago

Forte Biosciences initiated with a Buy at Guggenheim on FB102 potential

PremiumThe Fly

Forte Biosciences initiated with a Buy at Guggenheim on FB102 potential

10M ago

Forte Biosciences initiated with a Buy at Guggenheim

PremiumThe Fly

Forte Biosciences initiated with a Buy at Guggenheim

10M ago

Forte Biosciences Announces Q2 2025 Results and Trials

PremiumCompany Announcements

Forte Biosciences Announces Q2 2025 Results and Trials

10M ago

Forte Biosciences reports Q2 EPS (96c), consensus ($1.11)

PremiumThe Fly

Forte Biosciences reports Q2 EPS (96c), consensus ($1.11)

10M ago

Sixteen new option listings on July 23rd

PremiumThe FlySixteen new option listings on July 23rd

11M ago

Forte Biosciences Announces Public Offering of Shares

Company Announcements

Forte Biosciences Announces Public Offering of Shares

12M ago

Forte Biosciences announces common stock offering, no amount given

The Fly

Forte Biosciences announces common stock offering, no amount given

12M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >